Rheumatology CME/CE

Episodes 1-6 of 6

• • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Marina Magrey, MD

    Peer

  0

  

  RestartResume

  RestartResume

  0.25 credits

  Quality of Life in Patients with PsA: Disease Domain Impacts

  0.25 credits

• • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Siba Raychaudhuri, MD

    Peer

  3

  

  RestartResume

  RestartResume

  0.25 credits

  The Role of IL-17 in PsA Pathophysiology and Treatment Plans

  0.25 credits

• • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Marina Magrey, MD

    Peer

  0

  

  RestartResume

  RestartResume

  0.25 credits

  Comprehending the PsA Agents in Late-Stage Clinical Development

  0.25 credits

• • 

    

    William D. Tap, MD

    Peer

  • 

    

    Silvia Stacchiotti, MD

    Peer

  • 

    

    Michiel van de Sande, MD, PhD

    Peer

  • 

    

    Andrew J. Wagner, MD, PhD

    Peer

  6

  

  RestartResume

  RestartResume

  0.25 credits

  Improving Clinical Practices in the Management of Tenosynovial Giant Cell Tum...

  0.25 credits

• • 

    

    William D. Tap, MD

    Peer

  • 

    

    Silvia Stacchiotti, MD

    Peer

  • 

    

    Michiel van de Sande, MD, PhD

    Peer

  • 

    

    Andrew J. Wagner, MD, PhD

    Peer

  9

  

  RestartResume

  RestartResume

  0.25 credits

  Tenosynovial Giant Cell Tumor (TGCT): New Perspectives on Advances in Treatment

  0.25 credits

• • 

    

    Leonard H. Calabrese, DO

    Peer

  • 

    

    John R. Tesser, MD

    Peer

  1

  

  RestartResume

  RestartResume

  Pinpointing the Top Questions about Biosimilars in Rheumatology